Of A Patient With
B. Chief Complaint
Breast Mass (Left)
Sensation of breast pain
E. Family History
(+) Ovarian cancer sibling
F. PSHx
Menstrual History
Menarche: Around 13 y/o
Menopause: Around 49 y/o
First Child at age 34
Number of pregnancies: 6
(+) Breastfeeding
(+) Second hand smoker
(+) Alcohol intake (teen years), intake of carcinogenic foods (e.g. BBQ, canned goods)
G. Drug History
Date Monitoring
Medications Indications Dosing Duration
Ordered Parameters
11/15/16 Losartan Antihypertensive 100 mg Monitor CBC, HOLD on
12:00 PM potassium electrolytes, liver the day of
and kidney function operation
with long term (11/16/16)
therapy.
Monitor BP prior to 11/21/16
a scheduled dose.
Monitor drug
effectiveness
11/15/16 Simvastatin Antihyperlipidemic 20 mg Obtain baseline and HOLD on
8:00 PM periodic liver the day of
function during the operation
first year and yearly (11/16/16)
thereafter.
Monitor cholesterol 11/21/16
levels throughout
the therapy.
11/15/16 Clopidogrel Antithrombotic 75 mg Carefully monitor HOLD on
8:03 PM bisulfate for and immediately the day of
report signs and operation
symptoms of GI (11/16/16)
bleeding.
Periodic platelet 11/21/16
count and lipid
profile
11/17/16 Amodipine Antihypertensive 10mg Monitor BP for 11/21/16
7:45 AM besylate therapeutic
effectiveness.
Monitor for signs
and symptoms of
dose-related
peripheral or facial
edema that may not
be accompanied by
weight gain; rarely,
severe edema may
cause
discontinuation of
drug.
Monitor BP with
postural changes.
Monitor more
frequently when
additional
antihypertensives
or diuretics are
added.
Monitor heart rate;
dose related
palpitations may
occur.
Pre-op/Maintenance/Post-op Medications
Present Medication
1. Amlodipine 10mg once a day in the morning
2. Losartan 100mg once a day at noon
3. Simvastatin 20mg once a day at night
4. Clopidogrel 75 mg once a day at night
H. Physical Examination
GEN: Conscious
VITAL SIGNS:
BP: 130/80
HR: 65/min
RR: 18/min
BT: 36 O C
HEENT: Normal
CVS: Normal in Size and Shape
ABDOMEN: Left mass, Left upper chest quadrant mass
d. Ultrasound Report
- Liver is normal in size and parenchymal echopattern. No focal mass lesion seen.
- Intrahepatic and extrahepatic ducts are not dilated.
- Gallbladder is normal in size and configuration with smooth and not thickened wall.
- No intraluminal intense echo noted.
- Pancreas and spleen are normal in size and parenchymal echopattern. No focal mass
lesion seen.
- No paraaortic lymphadenopathy noted.
- Kidneys are normal in size and parenchymal echogenicity. No pelvocaliectasia nor lithiasis
noted.
- Urinary bladder is physiologically distended with smooth and not thickened wall. No
intravesical intense echo noted.
- Uterus is antaverted, normal in size and parenchymal echopattern. Endometrial stripe is not
thickened. Cervix is well coaptated.
- Ovaries are not visualized in this study due to intervening bowel gas.
- No evident adnexal mass noted.
- Clear cul-de-sac.
Impression:
- Negative ultrasound study of the hepatobillary tree, pancreas, spleen, kidneys and urinary
bladder.
- Normal anteverted uterus.
e. Surgical Intervention
Date of Operation: 11/16/16
Name of Procedure: Modified Radical Mastectomy
- This is a procedure in which the entire breast is removed, including the skin, areola, nipple,
and most axillary lymph nodes; the pectoralis major muscle is spared.
Intra-Operative Findings: Breast mass left
Post-Operative Diagnosis: Breast Carcinoma
Surgeon: Dr. F. Albano
Dr. Marcos
BREAST CANCER
Breast cancer is the most commonly diagnosed cancer among women, with approximately
182,000 women diagnosed with breast cancer annually in the United States, accounting for
approximately 26% of all incident cancers among women.
The cause of breast cancer is unknown, but the strongest risk factors for breast cancer are
female gender (this disease is about 100 times more common in women than in men. This
might be because men have less of the female hormones estrogen and progesterone, which
can promote breast cancer cell growth) and increasing age (usually in people aged 40 and
over). Additional risk factors include:
Endocrine factors:
Early menarche (Onset of menses before age 13)
Menses continuing after age 50
Nullipara (no experience of childbirth)
Late age at first birth (after age 30)
Hormone Replacement Therapy
Genetic Factors:
Personal and family history
- A woman with cancer in one breast has a higher risk of developing a new cancer
in the other breast or in another part of the same breast.
- Having a first-degree relative (mother, sister, or daughter) with breast cancer
almost doubles a woman’s risk.
Mutations of tumor suppresser genes
- About 5% to 10% of breast cancer cases are thought to be hereditary
- In some families with BRCA1 mutations the lifetime risk of breast cancer is as
high as 80%, but on average this risk seems to be in the range of 55% to 65%.
For BRCA2 mutations the risk is lower, around 45%.
Environmental and lifestyle factors (e.g. drinking alcohol, being obese)
b. Pathophysiology of Breast Cancer
Sex
Heredity
Environmental Agents
Immunologic Mechanisms
c. Clinical Symptomatology
Many women with early breast cancer have no symptoms however, late stages show the
most common symptom of breast cancer is a new lump or mass. A painless, hard mass that
has irregular edges is more likely to be cancerous, but breast cancers can be tender, soft, or
rounded. Other possible symptoms of breast cancer include:
swelling of all or part of a breast (even if no distinct lump is felt)
swelling of lymph nodes in the axillary area
breast skin irritation or dimpling
nipple pain
nipple retraction (turning inward)
redness, scaliness, or thickening of the nipple or breast skin
nipple discharge (other than breast milk)
d. Laboratory Findings
Screening tests: Screening exams, such as mammograms, find cancers before they start
to cause symptoms. Also, physical examination of the breast, and, possibly, other breast
imaging techniques, such as ultrasound and magnetic resonance imaging (MRI) provide
early detection which can be easier to treat and have better outcomes
Diagnostic tests: A biopsy is done when mammograms, other imaging tests, or the physical
exam shows a breast change that may be cancer. The surgeon makes an incision in the skin
and removes all or part of the abnormal tissue for examination under a microscope. A biopsy
is the only way to know for sure if it’s cancer.
Mainly, complications of other organs arise when cancer cells spread to different areas of the
body. Other complications are commonly due to different treatments of breast cancer which
include:
Chemotherapy. Chemotherapy attacks rapidly dividing cells. Cancer cells, along with
skin cells, and digestive tract cells are the most vulnerable to chemotherapy medication.
This can lead to hair loss, nausea, and vomiting. In premenopausal women, ovaries may
be damaged to the point that they stop producing hormones. This can cause early
menopausal symptoms such as vaginal dryness and hot flashes. Menstrual periods may
stop or become irregular. Getting pregnant may also become difficult. Women who
experience chemotherapy - induced menopause may also face a higher risk of
osteoporosis. The emotional distress of the experience may also cause the physical side
effects to feel more intense Some may have issues with concentration and memory loss,
known as “chemo-brain,” “chemo-fog,” or “chemo-memory,” but this is usually short lived.
Psychological side effects of chemotherapy and breast cancer itself also include
depression, fear, sadness, feelings of isolation, sleep disturbances
Radiation Therapy. Radiation therapy can result in more serious but slow-developing
and rare side effects. Serious complications include inflamed lung tissue, heart damage,
and secondary cancers. More common but less serious ones include skin burns,
irritation or discoloration, fatigue, and lymphedema.
Hormone Therapy. Some types of hormone therapy lower estrogen levels in women,
and increase the risk for osteoporosis. Lower estrogen levels also may lead to vaginal
dryness and irritation.
Mastectomy. complications include temporary swelling of the breast, breast tenderness,
hardness due to scar tissue that can form at the site of the incision, wound infection or
bleeding, swelling of the arm due to lymph node removal, called lymphedema, phantom
breast pain, including symptoms such as unpleasant itching, a sensation of “pins and
needles,” pressure, and throbbing
HYPERTENSION
The age-adjusted prevalence of hypertension was 34%, 25.4%, and 23.2% for men and
31%, 21%, and 21.6% for women among blacks, whites, and Mexican Americans,
respectively. Prevalence of hypertension was 12% for white men and 5% for white women
aged 18-49 years. However, the age-related BP rise for women exceeds that of men. The
prevalence of hypertension was reported at 50% for white men and 55% for white women
aged 70 years or older.
b. Pathophysiology
c. Clinical Symptomatology
If blood pressure is extremely high certain symptoms are: severe headache, fatigue or
confusion, vision problems, chest pain, difficulty breathing, irregular heartbeat, blood in
urine and pounding in your chest, neck, or ears.
b. Laboratory Findings
Hypertension often called as ‘silent killer’ because it is a disease that do not show early
symptoms and simultaneously is the single most significant risk factor for heart disease
and myocardial infarction, aneurysm, congestive heart failure, hypertrophy and chronic
kidney disease. The most frequent symptoms, headache, fatigue, dizziness and facial
flushing, are also very non-specific. Sub-occipital pulsating headaches, occurring early in
the morning and subsiding during the day, said to be characteristic, but any type of
headache may occur. Accelerated hypertension is associated with somnolence, confusion,
visual disturbances, nausea and vomiting (hypertensive encephalopathy.
c. Prognosis
The prognosis of hypertension is highly positive because it is almost always treatable with
dietary and lifestyles changes combined with medication. Patients will need to be
monitored several times a year to ensure that blood pressure has not spiked again and
that any treatments being used are still working. Sometimes medications or dietary habits
will need to be tweaked for optimum results.
HYPERLIPIDEMIA
Hyperlipidemia refers to any of several acquired or genetic disorders that resulting to high
level of lipids (fats, cholesterol and triglycerides) circulating in the blood. These lipids can
enter the walls of arteries and increase risk of developing atherosclerosis (hardening of
the arteries), which can lead to stroke, heart attack and the need to amputate.
a. Etiology
b. Pathophysiology
Causative factors:
Inherited mutation in genes
Deficiency in lipoprotein lipase enzyme
Disturbed functioning of LDL
risk factors:
High fat diet
Sedentary lifestyle
Atherosclerotic plaque
Retention in LDL
Oxidation and non-
enzymatic glycation
↑ LDL oxidation
Screening for hyperlipidemia is done with a blood test called a lipid profile. It is important that
a person has nothing to eat or drink for 9-12 hours prior to having the sample drawn.
Screening should start at age 20, and if normal, it should be repeated at least every five
years. Normal levels for a lipid profile are less than 200mg/dL for the total cholesterol, less
than 100mg/dL for LDL, greater than 40 for men, greater than 50 for women (higher is even
better) for HDL, and less than 140 for triglycerides.
Hyperlipidemia refers to increased levels of lipids (fats) in the blood, including cholesterol and
triglycerides. It can significantly increase the risk of developing cardiovascular disease,
including disease of blood vessels supplying the heart (coronary artery disease), brain
(cerebrovascular disease), and limbs (peripheral vascular disease). These conditions can in
turn lead to chest pain, heart attacks, strokes, and other problems.
f. Prognosis
Patients with hyperlipidemia are at extremely high risk of developing premature coronary
artery disease (CAD) (30%). If the disease is inadequately managed, the prognosis is poor,
especially if other cardiovascular risk factors are present. If the patient complies with lipid-
lowering therapy, dietary modification, and lifestyle modification and if therapy is successful,
outcome is improved significantly.
Objective:
Mammogram
Excision Biopsy Left Breast
NONE
Therapeutic Selection Resolutions/Recommendations (R)
Condition:
Breast cancer
Outcomes:
Improve symptoms, improve quality of life, and prolong survival.
Minimize need for reoperation
Slow the disease process
Prevention of disease recurrence
Regimen:
Docetaxel 80mg
Doxorubicin 50mg
Evaluation:
Patients should be asked about possible recurrence of symptoms
Evaluate modification lifestyle or daily activities
Monitor clinical signs of the serious complications of chemotherapy (e.g. leukemia and
heart disease).
P = Pharmaceutical-based Problems
Patient Non-compliance
R = Risk to Patient
Side effects of chemotherapy such as hair loss, nausea, and vomiting.
I = Drug Interaction
None
E = Efficacy Issues
Patient adherence to therapeutic lifestyle interventions is not guaranteed.
Subjective:
severe headache
chest pain
difficulty in breathing
pounding chest or neck
Objective:
Blood Pressure
Desired Outcomes Assessments (A)
Maintain BP within individually acceptable
range.
Minimize the complications of Hypertension
Adherence to drug therapy regimens should be
administered right after consultation and
therapeutic lifestyle should be followed
Desired End Points practice healthy living and improve quality of
life.
Drug-related Problems NONE
Condition:
Hypertension
Outcomes:
Maintain BP within individually acceptable range.
Minimize the complications of Hypertension
Regimen:
Losartan 50 mg
Amlodipine 10mg
Evaluation:
Close monitoring of blood pressure
Monitor patient’s response to therapy
Monitor patient’s sodium intake
Monitor healthy body weight
PRIME PHARMACOTHERAPY PLAN
P (Pharmaceutical-Based Problems)
Patient non-compliance
R (Risk to Patient)
Losartan – Increase risk of Hypotension, Renal impairment
Amlodipine – Peripheral Edema, Risk of angina and acute MI
I (Drug Interaction)
None
E (Efficacy Issues)
Patient non-compliance
Condition:
Hyperlipidaemia or Dyslipidemia
Outcomes:
Prompt resolution of the symptoms of disease after the introduction and initiation of
treatment
Minimize the risk of first or recurrent complications by lowering the total and LDL
cholesterol
Compliance to therapeutic lifestyle programs (e.g proper diet and exercise) and
drug-therapy regimens for reducing high cholesterol should start immediately.
Improve and ensure safe and quality of life.
Regimen:
Evaluation:
Lipid measurements should be obtained in the fasted state to minimize interference from
chylomicrons. Monitoring is needed every few months during dosage titration. Once the
patient is stable, monitoring at intervals of 6 months to 1 year is sufficient.
Patients on therapy should have a fasting panel checked every 4 to 8 weeks until a
stable dose is reached; triglycerides should be checked at a stable dose to ensure they
have not increased.
Patients receiving statins should have a fasting panel 4 to 8 weeks after the initial dose
or dose changes. Liver function tests should be obtained at baseline and periodically
thereafter based on package insert information. Some experts believe that monitoring for
hepatotoxicity and myopathy should be triggered by symptoms.
Patient non-compliance
Breast Cancer
Patients should be asked about possible recurrence of symptoms
Evaluate modification lifestyle or daily activities
Hypertension
Evaluate modification lifestyle or daily activities
Evaluate patient respond to therapy
Evaluate BP response 2 to 4 weeks after initiating or making changes in therapy.
Once goals BP values are obtained, monitor BP every 3 to 6 months, assuming
no signs or symptoms of acute target-organ disease.
Evaluate patients with a history of poor control, nonadherence, progressive
target-organ damage, or symptoms of adverse drug effects
Hyperlipidemia
Evaluate modification lifestyle or daily activities
Evaluation of short-term therapy for hyperlipidemia is based on response to diet
and drug treatment as measured by total cholesterol, LDL-C, HDL-C, and
triglycerides.
In patients treated for secondary intervention, symptoms of atherosclerotic
cardiovascular disease, such as angina and intermittent claudication, may
improve over months to years.
Patients receiving statins should have a fasting lipid panel 4 to 8 weeks after the
initial dose or dose changes. Obtain liver function tests at baseline and
periodically thereafter. Some experts believe that monitoring for hepatotoxicity
and myopathy should be triggered by symptoms.
For patients with multiple risk factors and established CHD, evaluate for progress
in managing other risk factors such as BP control, smoking cessation, exercise
and weight control, and glycemic control (if diabetic).
Evaluation of dietary therapy with diet diaries and recall survey instruments
allows information about diet to be collected in a systematic fashion and may
improve patient adherence to dietary recommendations.